EUVIMEDEUVIMED entdecken
Crossref

The safe dose for perfluorooctanoate: a commentary on the North American Federal perspective

Michael L. Dourson, Chijioke Onyema

Journal of Toxicology and Regulatory Policy · 2025

DOI: 10.69982/jtrp-24-0004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Toxicology and Regulatory Policy, 2025. Verfasst von Michael L. Dourson und 1 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Federal North American safe doses for the noncancer toxicity of perfluorooctanoate (PFOA) are sufficiently different that national authorities should work together to come up with a single value or perhaps a reasonable range. This range should include an appropriate measure for interspecies extrapolation depending on the critical effect, such as the maximum blood concentration, average blood concentration during a critical time, or area under the blood concentration–time curve. Available human clinical data for PFOA allows a comparison of kinetics between experimental animals and humans and should also be considered in the development of PFOA safe doses, since this may allow harmonization of disparate risk values.

Zitieren

APA

Dourson, M. L., & Onyema, C. (2025). The safe dose for perfluorooctanoate: a commentary on the North American Federal perspective. Journal of Toxicology and Regulatory Policy. https://doi.org/10.69982/jtrp-24-0004

Vancouver

Dourson ML, Onyema C. The safe dose for perfluorooctanoate: a commentary on the North American Federal perspective. Journal of Toxicology and Regulatory Policy. 2025. doi:10.69982/jtrp-24-0004

BibTeX
@article{Dourson2025,
  author = {Dourson, Michael L. and Onyema, Chijioke},
  title = {The safe dose for perfluorooctanoate: a commentary on the North American Federal perspective},
  journal = {Journal of Toxicology and Regulatory Policy},
  year = {2025},
  doi = {10.69982/jtrp-24-0004}
}
Kostenlos starten →